To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection
Aged 18-70 years, regardless of gender;
Positive 13C/14C urea breath test result;
No previous history of H. pylori eradication treatment;
Agreement to participate in this study and signing of the informed consent form.
History of ≥ 1 instance of failed H. pylori eradication;
Use of antibiotics (including antibacterial traditional Chinese medicines), nonsteroidal anti-inflammatory drugs (NSAIDS), bismuth agents, H2 receptor antagonists (H2RAs), proton-pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CAB) within 4 weeks before treatment;
Plans to conceive, pregnancy, or breastfeeding;
Severe liver, kidney, or cardiovascular diseases; malignancies; and alcoholism;
Parallel
Bismuth quadruple therapy
DrugBismuth quadruple therapy
Saccharomyces boulardii
DrugSaccharomyces boulardii
H. Pylori eradication rate
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
